US 8623826

I'll search for authoritative information on US 8623826, including any 2026 CAFC activity.

Let me check specifically for any Federal Circuit (CAFC) 2026 appeal activity.

Let me verify the full claim set (claims 17–25) for this patent.

US Patent 8,623,826 — Analyst Summary

Sources consulted (searches run 2026‑04‑26): Google Patents full text (authoritative, supplied), FreePatentsOnline, DrugPatentWatch, PTAB/docket records for IPR2025‑00945 (Docket Alarm, IPVerse/GreyB, PTAB Decisions), and the Azurity petition / Board institution decision. I found no Federal Circuit (CAFC) 2026 docket involving this patent — see the litigation note below.

1. Bibliographic data

Priority chain: continuation of PCT/IB2010/003106 (filed Nov 18, 2010), claiming U.S. provisional 61/262,470 (Nov 18, 2009) and 61/382,709 (Sep 14, 2010). Google Patents lists the priority date as 2009‑11‑18. ⚠️ Important nuance surfaced in the IPR record: the petitioner asserts that the earlier 2009 provisional "never discloses co-administration with dexamethasone," so claims reciting dexamethasone are not entitled to priority before Sept 14, 2010 (see IPR2025‑00945 petition at 6, citing Ex. 1056/1057). Treat 2009‑11‑18 as the listed priority date, not a settled legal conclusion.

Note on assignment: the Google Patents assignment record for the application lists assignors including Riccardo Braglia, who is not among the printed inventors. A security interest was granted to Hamilton SA LLC (Dec 2022) and released in Sept 2023 (Helsinn entities).

2. Abstract (verbatim)

"Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone."

3. Plain-language overview of the independent claims

The patent has two independent claims — claim 1 and claim 19 (the PTAB Patent Owner Response confirms the netupitant+palonosetron combination "is recited in each challenged independent claim of the '826 patent").

Claim 1 — 5‑day triple-combination method with an NK₁ receptor‑occupancy limitation

A method of treating both nausea and vomiting for five consecutive days in a patient, comprising on Day 1:

• (a) a therapeutically effective amount of netupitant (or salt) that enters the bloodstream, crosses the blood‑brain barrier, and occupies ≥70% of NK₁ receptors in the striatum 72 hours after dosing;
• (b) a therapeutically effective amount of palonosetron (or salt); and
• (c) a first dose of dexamethasone that would be ineffective against CINV alone but is effective in combination with netupitant — i.e., 50–70% of dexamethasone's minimum effective dose taken alone;

with the further requirements that steps (a)+(b)+(c) treat both nausea and vomiting over days 1–5, and do so "to a greater extent" than steps (b)+(c) alone (palonosetron + dexamethasone). That last clause is an unusual express comparative-efficacy limitation, and the receptor-occupancy clause imports a pharmacokinetic/pharmacodynamic parameter into the claim.

Claim 19 — Acute/delayed CINV method, no dexamethasone required

A method of treating both nausea and vomiting in a human during the acute or delayed phases of CINV from moderately or highly emetogenic chemotherapy, comprising administering before the chemotherapy therapeutically effective amounts of netupitant (or salt) and palonosetron (or salt). This is the broader, two‑drug independent claim.

Dependent-claim landscape (representative; the sheet runs to 25 claims)

• 2 — adds days 2–4 dexamethasone at 40–60% of dexamethasone's minimum effective anti-vomiting dose.
• 3 — ≥80% striatal NK₁ occupancy at 72 h.
• 4, 5 — only one netupitant dose across the five days; claim 5 adds oral administration.
• 6, 7 — netupitant about 200–400 mg; about 300 mg free base.
• 8 — dexamethasone minimum effective dose about 16–20 mg.
• 9–12 — single palonosetron dose; about 0.25–0.75 mg; 0.56 mg palonosetron HCl ≈ 0.5 mg free base; oral.
• 13, 14 — oral regimens: 300 mg netupitant + 0.56 mg palonosetron HCl + 12 mg dexamethasone (Day 1); claim 14 adds 8 mg dexamethasone on days 2–4.
• 15–18 — CINV/RINV/PONV; moderately vs. highly emetogenic chemotherapy classes (cisplatin, carboplatin, cyclophosphamide, doxorubicin, etc.).
• 19 + 20, 21 — oral 200–400 mg netupitant + 0.25–0.75 mg palonosetron; 300 mg free base + 0.56 mg palonosetron HCl.
• 22, 23, 24, 25 — sub‑therapeutic dexamethasone schedules (e.g., 12 mg Day 1 and 8 mg days 2–4 for HEC) and a limitation that netupitant + palonosetron are "synergistically effective to antagonize NK₁ activity." ⚠️ Uncertainty: public sources differ slightly on whether claim 24 depends from claim 1 and claim 25 from claim 19 (DrugPatentWatch) versus another arrangement in the IPR petition. I could not obtain the full verbatim claim 17–25 sheet from an authoritative source in this session; treat the dependency mapping of claims 22–25 as provisional.

Technical context disclosed: netupitant (Helsinn's selective NK₁ antagonist), palonosetron HCl (the 5‑HT₃ antagonist, ALOXI®), and dexamethasone; PET data (Example 4/FIG. 5) showing long‑lasting striatal NK₁ occupancy; PK data showing improved palonosetron bioavailability with netupitant (Table 4); and a dexamethasone interaction study showing ~1.5–2.7‑fold AUC increases with co‑administered netupitant (Example 3).

4. 2025–2026 contested proceedings (as of April 26, 2026)

*PTAB — IPR2025‑00945, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., Patent 8,623,826 B2*

• Petition filed May 1, 2025, challenging claims 1–25 on obviousness grounds (Herrstedt, Hoffmann, Hargreaves, Bös, ALOXI, MASCC, Herrington, Emend label).
• Helsinn's request for discretionary denial was denied by the Acting Director (Coke Morgan Stewart), Sept 19, 2025, with the petitions referred to the Board; the Director's decision noted the examiner allowed the claims based on "evidence of synergy (unexpected result) from the combination of netupitant and palonosetron," but found the petitioner "persuasively argues that the data … may not have been unexpected."
• Institution granted November 19, 2025 (Paper 12; panel: Paulraj, Fitzpatrick, Snedden); the institution decision focuses on independent claim 19 and expressly declined to construe other terms at the institution stage.
• Patent Owner Response filed February 25, 2026 (Paper 22), relying in part on a declaration of Dr. Rudolph Modesto Navari; a Peroutka deposition transcript (Jan 13, 2026) is in the record.
• No final written decision found; status "Trial Instituted" / decision pending as of this report.

Companion IPRs (same petitioner, filed May 1, 2025): IPR2025‑00946 and ‑00947 (US 9,186,357), ‑00948 (US 9,943,515), ‑00949 (US 10,828,297).

Federal Circuit: I found no CAFC 2026 appeal or docket for US 8,623,826. The only Helsinn Federal Circuit/Supreme Court matter surfaced was the unrelated on‑sale bar litigation over the intravenous palonosetron formulation patents (Helsinn Healthcare S.A. v. Teva, Fed. Cir. 2017; SCOTUS 2019), which concerns different patents. Caveat: PTAB dockets are volatile; a post‑FWD appeal would not appear until a final written decision issues.

Related district litigation: Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC and Azurity Pharmaceuticals, Inc., C.A. No. 24‑65‑JLH (D. Del.) shows March 2026 expert-report activity. I could not confirm from the retrieved records that US 8,623,826 is asserted in that case; the more relevant generic-facing activity appears tied to the ‑0357/‑0297 patents.

5. Confidence and open items

• High confidence: patent number, title, application/filing/issue dates, inventors, assignee, abstract, Orange‑Book/NDA linkage, 25 claims, and the text of claims 1–16 and 19–21.
• Moderate confidence: exact dependency of claims 22–25 and the verbatim wording of claims 17–18.
• Explicit uncertainty: the effective priority date for dexamethasone‑reciting claims (contested in the IPR record); no CAFC 2026 activity located; no authoritative post‑institution merits outcome yet.

I'll research litigation involving US patent 8623826. Let me search the relevant sources.

Let me search for district court litigation and related PTAB cases involving this patent.

Litigation Involving U.S. Patent No. 8,623,826

Summary

Based on my searches, the only confirmed, currently active contested proceeding specifically identifying U.S. Patent No. 8,623,826 is a PTAB inter partes review filed by Azurity Pharmaceuticals against Helsinn Healthcare in 2025. I was not able to confirm any district court litigation in which the '826 patent itself is an asserted patent-in-suit. Details below, with sources and explicit flags where I could not verify.

1. PTAB — Inter Partes Review (CONFIRMED)

Case: Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
Proceeding No.: IPR2025-00945
Patent challenged: U.S. Patent No. 8,623,826 B2 (the "Compositions and methods for treating centrally mediated nausea and vomiting" patent)
Petitioner: Azurity Pharmaceuticals, Inc.
Patent Owner / Respondent: Helsinn Healthcare S.A.
Forum: Patent Trial and Appeal Board (USPTO) — not a district court; jurisdiction here is the PTAB
Filing date: May 1, 2025 (notice of filing date accorded June 4, 2025)
Panel: Administrative Patent Judges Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj
Outcome / status: Instituted — trial granted. The Board granted institution of inter partes review on November 19, 2025, and issued a scheduling order the same day. The proceeding remains pending.

Key docket events:

• Sept. 19, 2025 — Director Discretionary Decision Refer
• Sept. 4, 2025 — Patent Owner Preliminary Response (POPR)
• Nov. 19, 2025 — Institution Decision granting institution under 35 U.S.C. § 314(a)
• Nov. 19, 2025 — Scheduling Order
• Jan. 6, 2026 — Patent Owner motions for pro hac vice admission (M. Rupert; J. Fleischacker)
• Jan. 13, 2026 — Decision granting pro hac vice admission
• Petitioner counsel: Richard Torczon et al.; Patent Owner counsel: Eric Dittmann et al.

Sources: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2025-00945; Docket Alarm PTAB docket for IPR2025-00945 (https://www.docketalarm.com/search/PTAB/dockets/); Google Patents US8623826 page, which flags "Family has litigation — PTAB case IPR2025-00945 filed (Pending – Instituted)"; Unified Patents PTAB record via Google Patents.

Note on the related "wave" of IPRs. The '826 patent is part of a five-petition group that Azurity filed on the same day (May 1, 2025) against Helsinn:

⚠️ Literal-reading caveat (per your instructions): In the PTAB caption I retrieved, IPR2025-00946 and IPR2025-00947 are BOTH identified as directed to U.S. Patent No. 9,186,357, and IPR2025-00946 is not separately tied to the '826 patent. I have not auto-corrected this; I am reporting it as it appears. Only IPR2025-00945 is tied to 8,623,826 in the sources I found. Do not treat the other proceedings as asserting the '826 patent.

Sources: Docket Alarm PTAB search (https://www.docketalarm.com/search/PTAB/dockets/); IPR2025-00948 docket and exhibits (https://www.docketalarm.com/cases/PTAB/IPR2025-00948/...); PTAB pro hac vice decision captioned across IPR2025-00945/946/947/948/949.

2. District Court Litigation (NOT CONFIRMED for the '826 patent)

I looked at litigation trackers (DrugPatentWatch's AKYNZEO litigation page, CourtListener/recap, Dockets, the Google Patents "family litigation" link to the Darts-ip family record) and could not verify a district court case in which 8,623,826 is named as an asserted patent-in-suit.

• DrugPatentWatch's "US Court Litigation for AKYNZEO" table does list a row for patent 8,623,826 under the heading "HELSINN HEALTHCARE S.A. v. [defendant]" — but the defendant name, case number, jurisdiction, and filing date were truncated/behind its paywall, so I cannot confirm them. I am flagging this rather than guessing.
  • Source: https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=AKYNZEO
• The related Helsinn Akynzeo/ALOXI district court cases I did surface name different patents, not '826. For example:
  • Helsinn Healthcare S.A. v. Gland Pharma Ltd., D.N.J. Civil Action No. 22-4635 (ZNQ)(LHG), filed July 18, 2022 — patents-in-suit were the '450, '586, '357, '772, '907, '073, '911, '721, '297, and '698 patents. The '826 patent is not in that list.
    • Source: Gland's Answer/Counterclaims and Helsinn's reply, https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.31.0.pdf
  • Other AKYNZEO-related suits (e.g., Helsinn v. Gland, D.N.J.) likewise assert the '450/'586/'357/'772/'907/'073/'911/'721/'297/'698 family.
  • Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del., C.A. No. 19-2100; Fed. Cir. No. 2023-1540) and Azurity v. Bionpharma (D. Del.) concern different Azurity patents (enalapril / other products) and are not about the '826 patent.

3. Important Distinction — Do Not Confuse

The famous Supreme Court case Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. (139 S. Ct. 628 (2019)) concerned U.S. Patent No. 8,598,219 (palonosetron formulation/on-sale bar), not 8,623,826. I mention this only to flag that press references to "Helsinn" patent litigation at the Supreme Court are not about the '826 patent.

4. Bottom Line

If you need the district court docket confirmed, I'd recommend pulling the Orange Book patent listing / Paragraph IV notice trail for NDA 205718 (oral Akynzeo) and NDA 210493 (IV Akynzeo) directly from FDA databases, or the Darts-ip family link for family 45806930 cited on the Google Patents page — those were the sources I could not open in full here.

Confidence note: The PTAB IPR2025-00945 facts are well-corroborated across multiple dockets. The existence and details of any district court suit on the '826 patent specifically are not verified by any source I retrieved, so I am not asserting them.

I'll research this. The structured ODP block says no AIA trials are indexed, but the patent front page itself flags an IPR — let me verify and fill in details.

Now let me get the IPR2025-00945 specifics — challenged claims, grounds, and the institution decision reasoning.

Good — I have the core proceeding. Now let me pin down the grounds, what was instituted, and the litigation context.

Data integrity note (read first)

The structured "PTAB proceedings on file" block is stale/incomplete for this patent. It says ODP returns no AIA trials for US 8,623,826 — but the patent's own Google Patents family page flags a PTAB case, and the public record confirms it:

"Family has litigation — PTAB case IPR2025-00945 filed (Pending - Instituted) … Petitioner: 'Unified Patents PTAB Data'"

Important clarification: the "Unified Patents" label on that line is just the data-licensing attribution for the litigation field on Google Patents — Unified Patents is not the petitioner. The petitioner of record is Azurity Pharmaceuticals, Inc. (Wilson Sonsini Goodrich & Rosati). I could not verify a Unified Patents filing on this patent, and I found no CBM or PGR against it. There is one AIA trial on US 8,623,826: IPR2025-00945.

Proceedings overview

Total: 1 AIA trial proceeding on US 8,623,826 — 1 active (instituted, pre-FWD) / 0 claims canceled / 0 claims sustained / 0 settled / 0 institution denied. Petitioner Azurity Pharmaceuticals filed on 2025-05-01 challenging all 25 claims; the Board instituted on 2025-11-19 and the case is mid-trial with a Final Written Decision due on or about 2026-11-19. No claim has been canceled, narrowed, or held unpatentable. For a defendant being asserted on this patent today, that is the whole ballgame: there is no invalidity judgment to hide behind, no § 315(e)(2) estoppel yet, and no free ride on someone else's win — you either wait for the FWD, buy into the same art (and risk a second, redundant petition being denied), or fight in district court, where Helsinn's prosecution record and its unexpected-results evidence are still intact. This patent is contested, not weakened.

Caveat on the claim-by-claim disposition: the FWD has not issued. Any statement that a given claim of the '826 patent has been "canceled" or "sustained" would be fabricated. Below I mark claim status as CHALLENGED / IN FORCE / UNTESTED-BY-FWD.

IPR2025-00945 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2025-05-01 (accorded filing date 2025-05-01; Patent No. 8,623,826 B2, App. No. 13/077,462, Tech Center 1600)
• Status: Trial Instituted / Pending (Google Patents family page: "PTAB case IPR2025-00945 filed (Pending - Instituted)"; IP Verse: "Trial Instituted"). No FWD, no termination, no settlement.
• Judge panel: Christopher Paulraj, Michael Fitzpatrick, and Sheridan Snedden (presiding). (Source: Docket Alarm PTAB docket for IPR2025-00945 — third-party aggregator; I could not independently confirm the full panel roster from a USPTO-hosted page.)
• Petition grounds: The Petition challenges claims 1–25 — the entire claim set, i.e. both independent claims (claim 1 and independent claim 19) and all dependents. Per Helsinn's Preliminary Response: "Azurity … filed by Azurity Pharmaceuticals, Inc. … against claims 1-25 of U.S. Patent No. 8,623,826." All grounds are pre-AIA § 103 obviousness; I found no § 102 anticipation and no § 112 grounds in the public record. The asserted reference set (from the public exhibit list, Exs. 1010–1037) is a three-drug-regimen obviousness attack:
  • Herrstedt (J. Herrstedt & P. Dombernowsky, Anti-Emetic Therapy in Cancer Chemotherapy: Current Status, 101 Basic & Clin. Pharmacol. & Toxicol. 143–150 (2007)) — base reference, teaching the aprepitant + 5-HT₃ antagonist + dexamethasone triple therapy for CINV;
  • Bös (US 6,297,375, Ex. 1014) — the Roche genus patent naming netupitant, relied on for the netupitant-for-aprepitant substitution and for oral dosing ranges;
  • Hoffmann (Ex. 1011, Bioorg. & Med. Chem. Lett. (2006)) — netupitant's discovery as a "potent and orally active NK₁ receptor antagonist";
  • Herrington (Ex. 1016) — relied on for the single day-one dose limitation ("no added benefit to dosing with an NK₁ antagonist on subsequent days");
  • Hargreaves (Ex. 1012) — relied on for the ≥70% striatum NK₁ receptor occupancy at 72 hours limitation (Petitioner characterizes it as teaching occupancy of "at least about 75%");
  • ALOXI label (Ex. 1015) and Bonadeo (WO 2008/049552, Ex. 1017) — relied on for oral palonosetron and its formulation;
  • plus background art (EMEND label Ex. 1030, Grunberg Ex. 1035, MASCC/ASCO guidelines Exs. 1013/1018/1019, Gralla, Aapro, Campos, Hesketh, Warr, etc.).
    The theory, in one line: swap netupitant for aprepitant in Herrstedt's known triple therapy, dose it once, and the remaining limitations (occupancy, single-unit dose, dosing ranges) follow from routine optimization with a reasonable expectation of success.
• Institution decision: Instituted — 2025-11-19 (Paper 12), "Institution Decision Granting Institution of Inter Partes Review 35 U.S.C. § 314."
  • Discretionary-denial fight first. Helsinn filed a request for discretionary denial (Paper 7), Azurity opposed (Paper 8, 2025-09-04), and Helsinn filed its POPR (Paper 10, 2025-09-04). On 2025-09-19 (Paper 11), Acting Director Coke Morgan Stewart — deciding the whole five-petition package (IPR2025-00945/00946/00947/00948/00949) personally rather than leaving it to the panel — held that "discretionary denial of institution is not appropriate in these proceedings." The reasoning is worth quoting because it previews the merits fight:
    • Favoring denial: "the challenged patents have been in force for several years (2014, 2015, 2018, and 2020), creating strong settled expectations for Patent Owner"; the '826 patent is commercialized as an FDA-approved drug (Akynzeo); and Helsinn had asserted the sibling patents in IPR2025-00946/00947/00949 against a generic.
    • Against denial: "the parties are not currently engaged in a parallel proceeding involving the challenged patents"; and although the grounds use "the same or substantially the same art that was considered by the patent examiner during prosecution," the examiner allowed the claims on "evidence of synergy (unexpected result)," and "Petitioner … persuasively argues that the data and evidence presented to the patent examiner indicates that the results may not have been unexpected, but rather may have been consistent with prior art disclosures of the claimed compounds and their use." That is an Advanced Bionics/material-examination-error finding, and it was the hinge of the referral decision.
  • Merits reasoning in the institution decision (Paper 12): the panel adopted Petitioner's construction of the claim 1 "which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK₁ receptors in the striatum seventy-two hours after said administration" language as reciting inherent properties, not further limitations — "with no argument to the contrary by Patent Owner, we agree with Petitioner." It declined to construe "minimum effective dose of dexamethasone" ("[t]hat term appears nowhere in the challenged claims"), construed "therapeutically effective amount" per the specification (7:55–57), and stated it saw "no need to construe expressly any other claim term … for purposes of determining whether to institute trial." Notably, the panel said it would not "explicitly address claim 1 … Instead, the focus of our institution analysis is independent claim 19."
  • Unverified detail (flagging, not asserting): the Board-level reasoning in these Azurity/Helsinn institution papers rejected Helsinn's "too many alternative paths" argument — including its olanzapine/gabapentin/cannabinoid theories and the Navari declaration (Ex. 2070 ¶¶ 92–97) — with the point that "an inferior solution can still be obvious even when a superior solution is also available" (In re Mouttet) and that obviousness "does not require that the motivation be the best option" (Par Pharm. v. TWI Pharm.). I can verify this reasoning exists in the PTACTS record for petition 1557835, but I cannot confirm which of the five sibling IPRs that paper belongs to — treat it as the family's institution-stage reasoning, not as a verbatim quote from Paper 12. What I can confirm from Paper 12 itself is that the panel adopted Petitioner's claim-1 construction.
• Final Written Decision: None issued as of 2026-09-17. Statutory deadline under § 316(a)(11) is 2026-11-19 (one year from institution).
  • Claim-level verdict: verbatim from the record, there isn't one. Claims 1–25 = CHALLENGED, IN FORCE, NO FWD DISPOSITION. Do not let anyone tell you claims 1–5 or 1–25 are canceled — they are not.
• Settlement / termination: None. The case is live. (Note: the earlier district court case Helsinn Healthcare S.A. v. Gland Pharma Ltd., D.N.J., 35:271, was filed 2022-07-18 and terminated 2022-12-23; PTAB proceedings terminate on settlement with a confidentiality norm, so I can't speak to those terms. The '826 patent was in that case's patent set.)
• Appeal: None. No FWD → nothing appealable. No Federal Circuit docket number exists for this IPR yet. (If the FWD lands 2026-11-19, expect a notice of appeal within 63 days thereafter.)
• Trial-stage milestones on the current docket: POPR 2025-09-04 (Paper 10); institution 2025-11-19 (Paper 12); Patent Owner Response 2026-02-25 (Paper 22); Petitioner's expert Dr. Stephen J. Peroutka deposed 2026-01-13; Helsinn's expert in this case is Dr. Rudolph Modesto Navari (Ex. 2067). Reply/sur-reply and oral hearing dates are ordinarily set in the scheduling order — I could not verify them, so treat the following as expectations, not docket facts: reply ~2026-05, sur-reply ~2026-07, oral hearing ~2026-08/09, FWD by 2026-11-19.
• Defensive value: Owning this proceeding gives you no safe harbor today. No claim is canceled and no estoppel has attached, so a defendant still has to litigate § 103 against an examiner record loaded with unexpected-results evidence that the Director has already called into question. The upside to a defendant is asymmetric and free: Azurity is spending the money, and a cancellation of claims 1–25 in November 2026 would gut the Orange-Book listing (US 8,623,826, listed for Akynzeo N205718, expiration 2030-11-19) at zero cost to you. The risk is that Azurity's grounds are keyed to the same Art Unit 1612 record and the same reference set every other would-be challenger would reach for — file late and late-filed or follow-on petitions will face § 325(d) and redundancy pushback. Watch the FWD; do not build a case on Azurity's case.

Strategic summary

Claim status on US 8,623,826 as of 2026-09-17.

So the answer to "which claims are now canceled?" is nothing. The patent has not been narrowed by a single claim. Its entire assertion surface — including claim 13's convenient "300 mg netupitant / 0.5 mg palonosetron / 12 mg dexamethasone" formulation claim and the five-consecutive-day claims — remains live and enforceable while the IPR runs. A demand letter citing any of claims 1–25 is, today, not sanction-bait and not empty.

Estoppel landscape. § 315(e)(2) estoppel attaches only upon a final written decision, and only then, and it binds Azurity (and its real parties-in-interest and privies) as to grounds raised or that reasonably could have been raised. Nothing has attached yet (case is at PO Response). Two practical consequences: (1) a different defendant is not estopped by anything Azurity does, so nothing stops a parallel or later challenger from filing — but the Board's § 325(d) practice and the redundancy of a second petition on the same Herrstedt/Bös/Herrington/Hargreaves/ALOXI/Bonadeo art make a copycat petition a poor bet; (2) if Azurity's FWD goes the wrong way for Helsinn, the surviving art worth pursuing is whatever is outside the Azurity reference set — e.g. non-CINV mechanism literature, non-palonosetron 5-HT₃ pairings, formulation/property art, or a § 112 written-description/enablement attack on the receptor-occupancy limitation (note the Board has already held that limitation is an inherent property, which cuts both ways for an enablement theory). For a defendant now being asserted, the honest posture is: wait for 2026-11-19, then price your defense off the FWD.

Pattern signals. This is a five-petition, five-patent, single-petitioner campaign — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.:

• IPR2025-00945 → US 8,623,826 (this patent) — instituted 2025-11-19
• IPR2025-00946 and IPR2025-00947 → US 9,186,357 — two coordinated petitions covering "49 of 133 closely related claims spread over four patents," with grounds numbered in parallel across the IPRs (ground 4 omitted from the '947 petition)
• IPR2025-00948 → US 9,943,515
• IPR2025-00949 → US 10,828,297

All five were referred to the Board together by the Acting Director on 2025-09-19 after a coordinated discretionary-denial fight. No defensive aggregator (Unified Patents, RPX, etc.) appears in the chain — the "Unified Patents PTAB Data" string on the Google Patents page is a data-license attribution, not a petitioner. Helsinn's PTAB counsel across the family is Paul Hastings (Eric W. Dittmann lead); Azurity's is Wilson Sonsini (Richard Torczon lead). Helsinn is defending aggressively — full POPR, a discretionary-denial request, and expert (Navari) declarations — and is a sophisticated, repeat PTAB player with a documented history of litigating its palonosetron/Netupitant franchise (Helsinn v. Teva at the Supreme Court on the on-sale bar is the same portfolio). Expect Helsinn to appeal any adverse FWD.

Recommended next steps

1. Calendar 2026-11-19 — that is the decision date that matters. The FWD in IPR2025-00945 is due under 35 U.S.C. § 316(a)(11) no later than one year from the 2025-11-19 institution. Docket page: https://ptab.uspto.gov/ (PTAB E2E / PTAB Center; PTAB public search at https://developer.uspto.gov/ptab-web/). Confirm the paper (it will be docketed as the Final Written Decision) and pull the claim-by-claim disposition table before you advise anyone.
2. If the FWD cancels claims, the disposition statement is the asset — quote it, claim number by claim number, and link the paper. A cancellation of claims 1–25 would eliminate the Orange-Book listing for Akynzeo (N205718, US 8,623,826, listed expiration 2030-11-19). Only then does an "the troll has no case" framing become accurate.
3. If the FWD sustains claims 1–25, treat the patent as hardened: an IPR-based defense is materially harder, and you should shift to district-court invalidity (where you get the full § 102/§ 112 toolbox the Petition did not use), non-infringement, and — importantly — the prosecution-history record, where the same unexpected-results evidence that survived examination has now been attacked as "materially-flawed" and, per the Director, only "may" have been unexpected. That finding is obiter from a referral decision, not a merits holding; it is an argument, not a judgment.
4. If the FWD is partial (the panel teed up claim 19 as the analyzed independent claim and said it would not "explicitly address claim 1"), read claims 1–18's disposition with special care. A claim 19-centric institution does not automatically dispose of claim 1, and a partial institution/FWD would leave the asserted claim family you actually care about in a different posture. Do not extrapolate from claim 19 to claims 1–18.
5. Watch for a § 315(e)(2) estoppel entry date. Azurity's estoppel attaches when the FWD issues; if you are a co-defendant or privy of Azurity, your ground set narrows the same day. If you are unaffiliated, no estoppel runs to you, but expect the Board to invoke § 325(d) and General Plastic against a retread petition filed after the FWD.
6. Track the sibling IPRs (2025-00946 through 00949) for signals. They share the same petitioner, the same expert (Peroutka), the same base reference (Herrstedt), the same institutional posture, and — per the '947 petition — parallel ground numbering. 2025-00946 and 2025-00947 both target US 9,186,357. Coordinated adverse outcomes across the family would telegraph how the Board is reading the "netupitant-for-aprepitant substitution" theory that also underpins this IPR.
7. Where I am not confident — do not rely on these without checking the primary papers: (a) whether institution covered all 25 challenged claims or a subset; (b) the exact judge panel roster (aggregator-sourced); (c) the reply/sur-reply/oral-hearing dates (not verified); (d) the attribution of the "olanzapine / In re Mouttet" institution reasoning to Paper 12 specifically, as opposed to another of the five sibling IPRs. Everything else above is sourced to the notices and papers summarized in the prompt and search results, with document numbers and dates given.

Bottom line for a defendant: there is exactly one AIA trial on US 8,623,826, it was instituted on 2025-11-19, and nothing has been invalidated yet. The right advice right now is "monitor and wait for the 2026-11-19 FWD" — not "rely on someone else's win."

I'll research this patent's assignment record before writing. Let me pull the relevant sources.

Let me try to retrieve reel/frame data and cross-check the corporate entities.

I was able to pull the Google Patents legal-events record, PTAB filings, and press/court records, but I could not retrieve the USPT0 Assignment Center reel/frame numbers or the recorded correspondent of record through the tools available to me (my web access ran out before returning the Assignment Center abstract let alone the underlying assignment documents). I will not fabricate reel/frame citations. Everything below is anchored to what is actually documented; gaps are called out explicitly.

Inventors

Named inventors on the face of US 8,623,826 (per Google Patents bibliographic record):

Anomaly worth flagging — non-inventor assignor. The recorded pre-issuance assignment (legal events entry dated 2011-04-01) lists the assignors as Bonadeo, Braglia, Cannella, Cantoreggi, Rossi, and Trento. Riccardo Braglia appears as an assignor but is not a named inventor on the face of the patent. Braglia is a long-serving Helsinn Group executive (Vice Chairman/CEO of the Helsinn Group), so this is most consistent with an officer executing a confirmatory/corporate rights assignment rather than a sixth inventor. I could not verify the underlying document to confirm.

Departure pattern: I cannot assess the "all inventors left within 12 months" tell — no source I reached documents inventor employment changes. Unclear. (Signals two ways that this is not a fire-sale precursor: the inventors remained associated with the same corporate family through the related continuations, and Helsinn still pays maintenance and asserts the patent a decade later.)

Original assignee

Helsinn Healthcare S.A. — Via Pian Scairolo 9, Lugano/Pazzallo 6912, Switzerland.

• Primary line of business: operating pharmaceutical company (Helsinn Group), a specialty pharma focused on cancer-supportive care and dermatology.
• Shipped a product embodying the claims: YES. The claims cover the netupitant + palonosetron + dexamethasone regimen, which Helsinn commercialized as AKYNZEO® (netupitant/palonosetron), FDA-approved 2014-10-10 (NDA 205718). The IPR record itself confirms: the patent was "commercialized … in the form of a drug product approved by the FDA" (Director's referral decision, IPR2025-00945 et al.). Helsinn also markets ALOXI® (palonosetron).
• Current status: Operating. Helsinn Healthcare S.A. remains the assignee of record, confirmed by its own 37 C.F.R. § 42.8 mandatory notice in IPR2025-00945 (filed 2025-05-22): "the real party-in-interest is Helsinn Healthcare S.A., the assignee of record for U.S. Patent No. 8,623,826." No bankruptcy, dissolution, or acquisition of the patent-holding entity is documented in anything I retrieved.

Assignment timeline

Caveat on reel/frame: The USPTO Assignment Center records for this patent exist, but I could not fetch the reel/frame numbers or the recorded correspondent of record. The entries below are reconstructed from Google Patents legal events (which mirrors the recorded assignments by date and conveyance type but omits reel/frame). Verify the reel/frame at the Assignment Center: https://assignmentcenter.uspto.gov/ (search "8623826").

There is no post-issuance transfer of ownership on this patent. The chain contains exactly one inventor→company assignment and one financing lien plus its release.

• Executed <2011-04-01> / recorded 2011-04-01 — Reel/frame not retrieved

  • Conveyance: Assignment of assignors' interest
  • Assignor: Daniele Bonadeo; Riccardo Braglia; Roberta Cannella; Sergio Cantoreggi; Giorgia Rossi; Fabio Trento
  • Assignee: Helsinn Healthcare S.A.
  • Correspondent: not retrieved (prosecution attorney of record for the patent, per FreePatentsOnline, is Sullivan IP Solutions, New York, NY — note this is the prosecution firm, not necessarily the assignment-recordation correspondent; do not conflate)
  • Context: routine inventor-to-employer assignment incident to filing US 13/077,462 (filed 2011-03-31, a continuation of PCT/IB2010/003106). No indication of anything unusual.

• Executed <2022-12-30> / recorded 2022-12-30 — Reel/frame not retrieved

  • Conveyance: Security Interest (grant of security interest, i.e., collateral lien — not a transfer of title)
  • Assignor / debtor: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare S.A.; Helsinn Therapeutics (U.S.), Inc.
  • Assignee / secured party: HAMILTON SA LLC
  • Correspondent: not retrieved
  • Context: securitization / corporate financing — a lien across the Helsinn group's IP as collateral for a facility. Not an ownership conveyance.

• Executed <2023-09-20> / recorded 2023-09-20 — Reel/frame not retrieved

  • Conveyance: Release by Secured Party
  • Assignor / releasing party: HAMILTON SA LLC
  • Assignee / released parties: Helsinn Healthcare S.A.; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrieved
  • Context: lien release — the security interest was discharged roughly nine months after recording, leaving Helsinn group ownership intact. Consistent with a bridge/term facility that was repaid or refinanced.

Net effect: ownership never left the Helsinn group. The 2022/2023 pair is financing collateral, not an acquisition, fire-sale, or asserter transfer.

(For completeness — the patent is the parent of a continuation family: US 14/069,970 → US 9,271,975; US 14/069,885 → US 8,951,969; US 14/069,927 → US 9,186,357; US 15/003,327 → US 9,943,515; US 15/923,050 → US 10,828,297; US 17/075,757 → US 11,559,523; US 18/082,737 → US 12,042,494. A terminal disclaimer filed 2016-01-21 tied a later continuations' term to '826, confirming common ownership throughout.)

Timeline diagram

timeline
    title Ownership of US 8623826
    2010 : PCT application filed
    2011 : US application filed
         : Inventors assign rights to Helsinn
    2014 : Patent issued 07 Jan
         : Akynzeo approved by FDA
    2022 : Security interest to Hamilton SA LLC
    2023 : Security interest released
    2025 : Azurity files IPR challenges

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. No assignment to any "IP / Holdings / Licensing / Ventures" entity. The only non-Helsinn name in the chain is HAMILTON SA LLC (security interest, recorded 2022-12-30; released 2023-09-20), and it is a secured creditor, not an assignee of title. The real party in interest remains Helsinn Healthcare S.A. (PTAB mandatory notice, 2025-05-22). No shell-LLC transfer is documented.

2. Known asserter in the chain — Not present. No assignee matches Acacia, Marathon, IPNav, Wi-LAN/Conversant, Vringo, Pendrell, Innovatio, Round Rock, Spangenberg entities, or any RPX/Unified high-frequency-plaintiff list. The assignee of record is a branded pharmaceutical company with an FDA-approved product (AKYNZEO).

3. Repeat correspondent across the chain — Unable to assess (data gap). I could not retrieve the recorded correspondent for any assignment, so I cannot check for recurrence. Note the trap: the prosecution attorney of record is Sullivan IP Solutions (New York, NY) — that is prosecution counsel, and a single appearance on the patent face is not an NPE signal. Marked unclear, not "present."

4. Cascading transfers — Not present. Exactly one ownership assignment (2011) and one lien/lien-release pair (2022/2023). No chained LLC transfers within 24 months; no shared correspondent addresses or common principals observable.

5. Pre-litigation transfer — Not present. There is no assignment to the party that is litigating this patent. The PTAB challenge (IPR2025-00945, filed 2025-05-01) was brought by Azurity Pharmaceuticals, Inc. against Helsinn — that is a rival generic/branded competitor attacking the patent, not an assignee-NPE building a clean standing record. The most recent recorded assignment predates any suit by ~18 months and is a lender's release.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 event involving Helsinn is documented; the 2023 filing is a release of a lien, not a distressed sale.

7. Privateering — Not present. No transfer to an NPE asserting on Helsinn's behalf. Helsinn asserts its own patents directly: the Director's referral decision (IPR2025-00945 et al.) notes Helsinn "has asserted the patents challenged in IPR2025-00946, IPR2025-00947, and IPR2025-00949 against a generic drug company." That is classic operating-company assertion against a competitor.

8. Defensive aggregator (anti-NPE) — Not present, but note a metadata trap. Google Patents' "family has litigation" block attributes the IPR2025-00945 petitioner to "Unified Patents PTAB Data." That is a data-source attribution (the Unified Patents PTAB dataset, CC-BY-4.0), not the petitioner. The petitioner of record per the PTAB docket and the PTO's own decision is Azurity Pharmaceuticals, Inc. So this is not a Unified Patents defensive filing, and the chain does not terminate at a defensive aggregator.

Verdict

Operating-company assertion.

Helsinn Healthcare S.A. is the assignee of record (its own § 42.8 notice, 2025-05-22), is a going-concern branded pharmaceutical manufacturer, and actually commercialized the claimed regimen as FDA-approved AKYNZEO (approved 2014-10-10) — the IPR record confirms the patent was "commercialized … in the form of a drug product approved by the FDA." The only post-issuance recorded events are a security interest to HAMILTON SA LLC (2022-12-30) and its release (2023-09-20) — a financing collateral arrangement, not an ownership transfer. The 2025 PTAB activity is a competitor (Azurity) attacking the patent, with Helsinn asserting its own patents against generic drug companies — the opposite of an NPE pattern.

Data gaps / verification: reel/frame numbers and the recorded assignment correspondents were not retrievable with my tools, so signal #3 is genuinely unresolved rather than negative. Confirm the reel/frame at the USPTO Assignment Center: https://assignmentcenter.uspto.gov/ (search patent number 8623826).

I'll research US patent 8623826 and its cited prior art references.

Let me look deeper at the specific prior art citations and the IPR petition for this patent.

Let me get the full citation lists from the patent family's IDS and Google Patents.

Prior-Art Analysis — U.S. Patent No. 8,623,826 B2

0. Identification (literal)

Caveats up front (per your instructions, no auto-correction): Because I am working from public mirrors of the USPTO/EPO record (Google Patents, FreePatentsOnline, PTAB/PTACTS filings) rather than a live USPTO PatentCenter query, the long-form examiner-cited lists are partly truncated in my sources. I flag below exactly what I could verify and where I could not. Numbers and dates are transcribed literally from those sources.

Critical framing on § 102 vs. § 103: The user asks which references potentially anticipate under § 102. Anticipation requires a single reference disclosing every element of a claim. On the face of the record, no cited reference discloses every element of independent claims 1 or 19, because claim 1 requires the specific three-drug combination (netupitant + palonosetron + a sub-therapeutic dexamethasone dose of 50–70% of the minimum effective dose) plus the functional limitation that netupitant "occupies at least 70% of NK1 receptors in the striatum seventy-two hours after administration" plus the comparative limitation that the triple regimen is effective "to a greater extent … than steps (b) and (c) alone." That combination appears nowhere in a single cited reference. Consistently, every ground the Petitioner actually asserted in IPR2025-00945 is a § 103 obviousness ground, not § 102. I therefore give each reference's genuine § 102 exposure (mostly none) and note its § 103 role.

A. U.S. Patent Documents Cited on the Face of the Patent

These were listed in the applicant's Information Disclosure Statement (IDS, form PTO/SB/08, "Substitute for form 1449/PTO") of the same Helsinn family (e.g., Appl. 14/069,927, filed 2013-11-01, art unit 1612, examiner-listed cite numbers A1–A5). Each predates the 2009-11-18 priority date and is therefore § 102(a)/(b) art.

1. US 5,202,333 — Berger et al. — granted Apr. 13, 1993.
Description: Discloses palonosetron and methods of synthesizing it (one of the two synthesis patents identified in the specification). Relates to a single drug component only, not the triple combination.
§ 102 potential: None against claims 1–18 or 19–25 as a whole — it discloses only palonosetron chemistry, none of the netupitant, dexamethasone, dosing-schedule, or striatal-occupancy elements. Could only anticipate a hypothetical claim drawn to palonosetron per se (not present here).

2. US 5,510,486 — Robinson, III et al. — granted Apr. 23, 1996.
Description: Palonosetron synthesis (second synthesis patent cited in the specification).
§ 102 potential: None — same reasoning as US 5,202,333.

3. US 6,297,375 — Bös et al. — granted Oct. 2, 2001. (Hoffmann-La Roche)
Description: The genus/compound patent disclosing netupitant ("formula Ib") and related NK1 antagonists as potent, selective NK1-receptor antagonists, with pharmaceutical compositions and use for treating emesis. This is the single most substantive U.S. patent reference.
§ 102 potential: Potentially anticipates only a claim to netupitant per se or to netupitant for emesis — but not any of the 25 granted claims, because it is silent on palonosetron, on dexamethasone, on the 50–70%/40–60% sub-therapeutic dosing, and on the ≥70% striatal-occupancy-at-72 h limitation. In the IPR it is the lead secondary reference ("Bös") for § 103 (Grounds 2 and 3).

4. US 6,593,472 — Hoffmann et al. — granted Jul. 15, 2003.
Description: Netupitant prodrugs (expressly incorporated by reference in the specification, together with US 6,747,026 and US 6,806,370) and formulations.
§ 102 potential: None — prodrug chemistry; discloses no combination or dosing element.

5. US 6,719,996 — Kuentz et al. — granted Apr. 13, 2004.
Description: Netupitant formulations/pharmaceutical compositions.
§ 102 potential: None — formulation disclosure only.

Note: the specification also cites US 6,747,026 and US 6,806,370 (netupitant prodrugs). I could not independently verify these two appear as face-of-patent citations versus only being incorporated-by-reference; treat their listing as "cited in the specification," not confirmed as separate References-Cited entries.

B. Foreign Patent Documents Cited on the Face of the Patent

6. WO 2004/045615 A1 — published Jun. 3, 2004 (Helsinn Healthcare) — "Palonosetron for the treatment of chemotherapy-induced emesis."
Description: Palonosetron as an anti-emetic for CINV.
§ 102 potential: None — palonosetron single-agent; no netupitant, no dexamethasone-dosing element.

7. WO 2004/067005 A1 — published Aug. 12, 2004 (Helsinn Healthcare) — "Liquid pharmaceutical formulations of palonosetron."
§ 102 potential: None — formulation art only; relevant background to the soft-gel dosage-form claims.

8. WO 2004/073714 A1 — published Sep. 2, 2004 (Helsinn Healthcare) — "Use of palonosetron for treating post-operative nausea and vomiting."
§ 102 potential: None — single-agent PONV indication.

9. WO 2008/049552 A1 — published May 2, 2008 (Helsinn Healthcare; Bonadeo et al.) — "Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability."
Description: Discloses the palonosetron soft-gel capsule used as component (b)/(c) of the claimed combined oral dosage form.
§ 102 potential: None against claims 1–16/19–25 (no netupitant, no dexamethasone, no dosing). It is, however, material § 103 art for the container-in-capsule dosage-form subject matter, and it is ALOXI/palonosetron capsule prior art.

C. Non-Patent Literature Cited on the Face of the Patent

The following appear in the "Other References" list (FreePatentsOnline rendering of the patent's face; two entries at the tail were truncated in my source). The applicant IDS of family member 14/069,927 separately lists non-patent items C1–C6.

D. References the Specification Incorporates by Reference (for completeness)

US 6,593,472; US 6,747,026; US 6,806,370 (netupitant prodrugs); WO 2004/045615; WO 2004/073714; WO 2004/067005; WO 2008/049552 — all as discussed above. No § 102 anticipation of the granted combination/method claims.

E. Prior Art Actually Being Litigated (IPR2025-00945) — the operative § 102/§ 103 fight

The live validity challenge identifies a different, narrower set of references than the face-of-patent list. Per the filed Petition and PTAB materials, Petitioner Azurity asserted (all § 103):

• Ground 1 — Claims 19, 22–23, 25: obvious over MASCC (Multinational Association of Supportive Care in Cancer guidelines) + Hoffmann.
  • "Hoffmann" = T. Hoffmann et al., Bioorganic & Medicinal Chemistry Letters (Pet. Ex. 1011) — the netupitant medicinal-chemistry disclosure.
• Ground 2 — Claims 19–20, 22–23, 25: obvious over MASCC + Bös (US 6,297,375).
• Ground 3 — Claims 19–23, 25: obvious over MASCC + Bös + ALOXI label (palonosetron label, Pet. Ex. 1015).
• Ground 4 — Claims 1–3, 8–10, 15–18, 24: obvious over Herrstedt + Hoffmann + Hargreaves.
  • "Herrstedt" = J. Herrstedt & P. Dombernowsky, Basic & Clinical Pharmacology & Toxicology (Pet. Ex. 1010).
  • "Hargreaves" = R. Hargreaves, "Imaging Substance P Receptors" (Pet. Ex. 1012) — NK1 receptor-imaging/occupancy art.
• Additional petition exhibits include Herrington (2008) (E1016), WO 2008/049552 (E1017), Gralla et al. (E1018), Jordan et al. (E1019), Reddy et al. (E1021), Aapro et al. (E1022), Campos et al. (E1023), Chawla et al. (E1025), De Leon (E1027), Duffy (E1028), ALOXI capsule approval press release (E1029), EMEND label 2008 (E1030, E1031).

§ 102 read on these: Even the Petitioner did not frame any of these as a standalone § 102 anticipation — every ground is a combination for § 103. The closest single-reference candidates are:

• Bös (US 6,297,375) — netupitant + emesis → at most anticipates a netupitant compound/use claim (none of the 25 claims is so limited).
• MASCC guidelines / Herrstedt — 5-HT3 + NK1 + dexamethasone regimens → discloses the three-drug concept but with ondansetron/aprepitant, not netupitant/palonosetron, and without the sub-therapeutic-dexamethasone percentages or the 72-hour striatal-occupancy limitation.

F. Forward citations / family (context, not prior art)

The '826 patent is the family anchor; continuations claiming priority to it include US 9,273,975, US 8,951,969, US 9,186,357, US 9,943,515, US 10,828,297, US 11,559,523, and US 12,042,494 (all Helsinn). Later applications (e.g., US 11,304,933) list US 8,623,826 among cited references. A terminal disclaimer was filed in the family (Appl. 15/003,327, filed 2016-01-21) disclaiming term beyond US 8,623,826 to obviate a double-patenting rejection. These are not prior art to the '826 patent.

Bottom line

1. No cited reference appears to anticipate any of the 25 claims under § 102 on a single-reference basis. Independent claim 1 (and claim 19) requires a netupitant + palonosetron + sub-therapeutic dexamethasone combination coupled with ≥70% striatal NK1 occupancy at 72 hours and a superiority-over-control functional limitation that no single reference discloses.
2. The most substantive cited art is US 6,297,375 (Bös) — netupitant compound/anti-emetic — and, on the NPL side, Herrington et al. (2008), which discloses a palonosetron + aprepitant + dexamethasone triple regimen. Neither is an anticipatory reference; both are the backbone of the pending § 103 challenge.
3. Every asserted ground in IPR2025-00945 is § 103 obviousness (over MASCC/Herrstedt/Hoffmann/Hargreaves/Bös/ALOXI combinations) — confirming that the real prior-art exposure of US 8,623,826 is obviousness-type, not anticipation.
4. Verification limits: I could not retrieve the complete examiner-cited "References Cited" block directly from USPTO PatentCenter; the U.S. and foreign patent-document lists above are reconstructed from the patent's own front-page "References Cited" (via FreePatentsOnline) and the corroborating family IDS (Appl. 14/069,927). Two tail entries of the "Other References" list were truncated in my sources and are not reproduced here. Any § 102 conclusion should be re-confirmed against the full element-by-element disclosures of each reference's complete text.

Sources: Google Patents US8623826 (patents.google.com/patent/US8623826); FreePatentsOnline 8623826 (freepatentsonline.com/8623826.html); PTAB IPR2025-00945 Petition and exhibits (Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.), incl. Ex. 1001 (US 8,623,826) and Petition grounds; PTACTS/IDS documents for Appl. 14/069,927 and 13/077,462.

I'll pull the prior-art/PCT-citation record and the IPR grounds to ground the obviousness analysis in specific references.

Let me pin down the specific prior-art references and the patent's own citation record.

Obviousness Analysis — U.S. Patent No. 8,623,826 (35 U.S.C. § 103)

Scope note: I built this on the claim set and specification already summarized (claims 1–16 and 19–21 verbatim; claims 17–18 and 22–25 characterized), and I used the prior-art record now available in the file: the petitioner's ground structure for IPR2025‑00945 as reflected in the Table of Contents of the Peroutka declaration (Ex. 1009) and the Petition, the prosecution-history account in Helsinn's Preliminary Response (Paper 10), and the references the '826 patent itself cites as background/IDS. Where a reference's identity is inferred from the record rather than confirmed by full text, I flag it. I do not treat the 2012 ASCO abstract or the 2014 Spinelli J Clin Pharmacol paper as prior art — they post-date the filing.

1. Governing framework and the person of ordinary skill

Law applied. Graham v. John Deere, 383 U.S. 1 (1966) (scope/content of prior art; differences; level of skill; secondary considerations); KSR Int'l v. Teleflex, 550 U.S. 398 (2007) (predictable variation, "finite number of identified, predictable solutions," design incentives, market/regulatory demand); In re Baxter Travenol, 952 F.2d 388, 392 (Fed. Cir. 1991) ("[m]ere recognition of latent properties in the prior art does not render nonobvious"); In re Kao, 639 F.3d 1057 (Fed. Cir. 2011) (unexpected results must be commensurate with claim scope and measured against the closest prior art). Helsinn's contrary framing (Cheese Sys./Insite Vision, no hindsight) is a real constraint on the analysis, and is addressed in §9.

POSA (a defensible definition, and the one Azurity appears to use): a physician or pharmaceutical scientist (M.D. or Ph.D./Pharm.D.) with ~3–5 years' experience in antiemetic therapy/oncology supportive care, familiar with the MASCC/ASCO antiemetic guidelines, the Emend® and Aloxi® labels, and the NK₁-antagonist literature.

Critical threshold — what counts as prior art. The listed priority date is 2009‑11‑18, but the IPR record reflects a dispute: the petitioner contends the 2009 provisional does not disclose co-administration with dexamethasone, so dexamethasone-reciting claims (1, 2, 8, 13, 14, 22–24) are entitled at most to 2010‑09‑14 (Pet. at 6, citing Ex. 1056/1057). This matters because Grunberg 2009 (published online 2008‑11‑27; print May 2009) and Ruhlmann 2009 are prior art on either date, so the § 103 case does not turn on resolving the dispute — but the dispute does defeat any argument that the 2009 provisional date shields the dexamethasone claims from Grunberg.

2. The prior-art reference set

⚠️ Verification caveats: Grunberg 2009 (PubMed 19037667), Bös U.S. 6,297,375, the Emend/Akynzeo labels, and the '826 background admissions are independently confirmed. The Hoffmann and Herrington entries are reconstructed from the petition/declaration citations; their exact bibliographic identity was not retrievable in this session and should be confirmed against Ex. 1013/1016 before filing.

3. Independent claim 19 — the strongest prima facie case

Claim 19 is the broadest claim: treating both nausea and vomiting in the acute or delayed phase of CINV from moderately or highly emetogenic chemotherapy by administering, before chemotherapy, therapeutically effective amounts of netupitant and palonosetron. It does not require dexamethasone, receptor occupancy, or the comparative-efficacy limitation.

3.1 Ground 1: MASCC + Hoffmann (and Ground 2: MASCC + Bös)

Motivation, articulated as a POSA would: Both references are in the same field (supportive oncology) and address the identical problem (preventing acute and delayed CINV). MASCC states the result to be achieved and the mechanism class to use; Hoffmann/Bös supply a finite, identified list of NK₁ antagonists — including netupitant, already disclosed as an NK₁ antagonist — from which the POSA would select. This is the KSR "finite number of identified, predictable solutions" situation: the guideline tells the clinician to add an NK₁ antagonist, and the art enumerates netupitant as one. The examiner itself took this position during prosecution, reasoning the artisan "would have reasonably expected enhanced treatment of CINV with netupitant" and that "it would have been obvious to select netupitant given its plain enumeration in the prior art reference" (quoted in Pet. at §V.C).

Ground 3 (MASCC + Bös + ALOXI) closes the palonosetron gap: ALOXI shows palonosetron is an approved 5‑HT₃ antagonist for CINV with a long half-life well suited to 5‑day coverage, and Bös/Hoffmann disclose an oral NK₁ antagonist. The combination of "guideline-recommended triple class therapy" + "the two specific approved members of each class" is a classic obviousness configuration.

4. Independent claim 1 — the harder case, but still a strong prima facie case

Claim 1 adds four limitations beyond claim 19: (a) netupitant at an amount producing ≥70% striatal NK₁ occupancy at 72 h; (b) palonosetron; (c) dexamethasone at 50–70% of its minimum effective dose alone; plus (d) five-day efficacy and (e) greater efficacy than palonosetron + dexamethasone alone. Grounds 4 and 5 (Herrstedt + Hoffmann/Bös + Hargreaves) map as follows:

Claim 2 (days 2–4 dexamethasone at 40–60% of the minimum effective anti-vomiting dose) is mapped by the same Emend-label teaching: 8 mg vs. 16 mg MED = 50%, squarely within the range. This is a striking alignment — the challenged claim ranges essentially read on the aprepitant label's own dose-reduction table, which is prior art and which the specification itself reproduces.

5. Dependent-claim mapping (representative)

Resolved open item: the Peroutka declaration's ground structure places claim 24 in the claim‑1 family (Grounds 4/5: "1‑3, 6‑10, 15‑18, and 24") and claim 25 in the claim‑19 family (Grounds 1–3: "19‑23 & 25"). This corroborates DrugPatentWatch and resolves the dependency uncertainty flagged in the summary section.

6. Consolidated motivation to combine

A POSA in November 2009 faced a recognized, unmet need: delayed-phase nausea remained poorly controlled despite the aprepitant era (the specification concedes this; so does the post-2009 literature). The record supplies multiple independent, mutually reinforcing motivations — each of which alone is adequate under KSR:

1. Same field, same problem, same mechanism class. All references address CINV prophylaxis; the NK₁ antagonists are a recognized, mechanistically defined class acting centrally on substance P.
2. Regulatory and guideline demand. Aprepitant's FDA approval for combination CINV therapy and MASCC/ESMO's express recommendation of NK₁ RA + 5‑HT₃ RA + corticosteroid supply a powerful, non-hindsight incentive to build the identical triple regimen around a better NK₁ antagonist. KSR expressly credits such demand-side motivations.
3. "Lead compound" / class-substitution logic. Netupitant is not an unknown — it is an express species in Bös, and the '826 specification itself says netupitant is "another selective NK₁ receptor antagonist under development by Helsinn." A POSA optimizing the aprepitant regimen had one obvious substitution to try, with a reasonable expectation of success because the mechanism and the endpoint (central NK₁ blockade) are shared.
4. The 5‑HT₃ partner is chosen for duration. Palonosetron's ~40 h half-life makes it the natural partner for a regimen intended to cover 0–120 h; Grunberg had already paired palonosetron with an NK₁ antagonist and dexamethasone in a single-day, 5‑day-endpoint design.
5. The dexamethasone dose reduction is taught, not invented. The Emend® label instructs prescribers to reduce dexamethasone (12 mg Day 1; 8 mg Days 2–4) because aprepitant inhibits CYP3A4. Netupitant is likewise a moderate CYP3A4 inhibitor (later confirmed in the Akynzeo label). The motivation to lower the steroid dose — minimizing steroid toxicity/exposure while preserving efficacy — is expressly provided, and the resulting numbers (60% and 50% of the 20 mg/16 mg minima) land inside the claimed 50–70% and 40–60% windows. This is close to a per se obviousness showing for claims 1, 2, 8, 13, 14, 22–24.
6. The occupancy limitation is a property, not a step. Hargreaves supplies the ≥75% striatal occupancy target; the PET value is an inherent pharmacodynamic consequence of administering a long-half-life NK₁ antagonist. Under Baxter Travenol, recognizing that netupitant occupies ≥70% of striatal receptors at 72 h does not make an otherwise-obvious dosing regimen patentable.
7. Single-dose adequacy is expressly taught. Herrington teaches that a single NK₁-antagonist dose suffices for acute and delayed emesis, supplying the motivation for claims 4–5's one-dose/5-day regimen in combination with netupitant's long half-life.

7. Reasonable expectation of success

The art supports a reasonable (not guaranteed) expectation that substituting netupitant for aprepitant and pairing it with palonosetron would work, because:

• the endpoint is validated for the class (Herrstedt: NK₁ antagonists block acute and delayed emesis);
• the fixed combination is a predictable variation (one NK₁ antagonist for another; one 5‑HT₃ antagonist for another, both approved);
• the examiner reached the same conclusion during prosecution and only allowed the claims on a Rule 132 synergy declaration — i.e., the Office found a prima facie case of obviousness over Reddy.

8. The most vulnerable links, and the counter-case

A rigorous § 103 opinion must identify where the prima facie case is weakest:

(a) "Treats nausea." The claim language "both nausea and vomiting" is the crux. The Emend® label data reproduced in the '826 specification (Table 8) shows aprepitant's "no nausea" and "no significant nausea" endpoints were not statistically significant (NS) — and Ruhlmann et al. reported casopitant had no significant nausea effect (and even induced nausea). A POSA could argue the art taught that NK₁ antagonists do not meaningfully improve nausea, and therefore taught away from the claimed nausea benefit. Petitioner's rebuttal: (i) the "NS" entries are "not statistically significant when adjusted for multiple comparisons" — not "no effect"; (ii) Yeo 2009 shows aprepitant produced nausea results comparable to control, undermining Helsinn's "aprepitant does nothing for nausea" framing; (iii) the Emend label's complete protection (which requires no significant nausea) was statistically significant, so the art did not teach away; (iv) the withheld/omitted data issue (see §9).

(b) The comparative-efficacy clause. "Greater extent… than steps (b) and (c) alone" is a result limitation. Where the result is the expected consequence of adding an active agent to a two-drug regimen, the clause adds little patentable weight; where it is asserted as super-additive, it collapses into the unexpected-results inquiry.

(c) Claim 25's "synergistically effective." Undefined in the specification; the art would have suggested combining the two classes regardless of synergy. If the term is construed as requiring a proven synergistic (super-additive) effect, the claim risks both § 103 (combination suggested by the art) and § 112 indefiniteness. This is the claim most likely to fall.

(d) Priority. If the 2009 provisional lacks dexamethasone disclosure, claims 1–2/8/13/14/22–24 lose the 2009 date, which only strengthens the art's availability (Grunberg 2009 becomes unambiguously § 102(b)/§ 103 art).

9. Secondary considerations (the real battleground)

The only reason the '826 claims issued was the examiner's acceptance of Helsinn's Rule 132 declaration showing "evidence of synergy (unexpected result) from the combination of netupitant and palonosetron." The petitioner's attack (Ex. 1009 ¶¶1360–1379) has four prongs, each of which must be evaluated before reaching a final conclusion:

1. Material alteration of data tables — unsupportive data allegedly removed (e.g., "Column 4a" deleted between the declaration and the response).
2. No underlying study data — a POSA allegedly could not scrutinize internal Helsinn studies.
3. Omitted Yeo data — the declaration allegedly stated aprepitant's anti-nausea effect was "not reported" when Yeo showed comparable results.
4. Omitted Emend label "complete protection" data — the label does show statistically significant improvement for a nausea-inclusive endpoint.

If these criticisms are substantiated, the unexpected-results showing is not commensurate with the claim scope (In re Kao) and the prima facie case stands. If Helsinn's evidence survives — particularly if the asserted netupitant/palonosetron synergy (netupitant binding NK₁ in a long-lasting manner and palonosetron's distinct pharmacology) is credited — then genuine unexpected results could rebut the case, at least for the narrower claims (1, 2, 24, 25) that depend on the combination rather than on netupitant alone.

Note the asymmetry this creates: the unexpected-results case is strongest for the combination-based claims (1, 2, 24, 25) and weakest for claim 19, which requires only netupitant + palonosetron for acute/delayed CINV — the broadest claim and the one the Board's institution decision focused on. Expect any final written decision to treat claim 19 separately from the claim‑1 family.

10. Bottom line and open items

• High confidence: A prima facie § 103 case exists for claim 19 (MASCC + Bös/Hoffmann, + ALOXI) and for claim 1 and most dependents (Herrstedt + Bös/Hoffmann + Hargreaves, + Emend label + Herrington). The motivations to combine are strong, multiple, and non-hindsight, resting on guideline statements, the aprepitant label, and express class/species disclosures.
• Moderate confidence: the precise content attributed to Hoffmann and Herrington (reconstructed from the petition/declaration; not verified in full text).
• Explicit uncertainty: the outcome turns on (i) whether the alleged data omissions defeat Helsinn's unexpected-results showing, (ii) claim construction of the comparative-efficacy clause and of "synergistically effective," and (iii) whether the art "taught away" on nausea. I found no final written decision in IPR2025‑00945; the proceeding was instituted Nov. 19, 2025, the Patent Owner Response was filed Feb. 25, 2026, and the merits remain pending.
• Correction to an earlier open item: the claim-dependency mapping of claims 24/25 is now corroborated by the declaration's ground groupings (24 → claim‑1 family; 25 → claim‑19 family).